Does the media favor BLTE or URGN?

In the previous week, Urogen Pharma had 9 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Urogen Pharma and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.22 beat Urogen Pharma's score of 0.40 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, LNTH or URGN?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.16 Urogen Pharma $109.79M 17.03 -$153.49M -$1.98 N/A

Is LNTH or URGN more profitable?

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Urogen Pharma -51.73% N/A -43.79%

Does the media favor LNTH or URGN?

In the previous week, Urogen Pharma had 5 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Urogen Pharma and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.63 beat Urogen Pharma's score of 0.40 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to URGN or AMRX?

In the previous week, Urogen Pharma had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Urogen Pharma and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Urogen Pharma's score of 0.40 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LQDA or URGN?

Liquidia has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 15.16 -$68.92M $1.37 19.57 Urogen Pharma $109.79M 17.03 -$153.49M -$1.98 N/A

Is LQDA or URGN more profitable?

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Urogen Pharma -51.73% N/A -43.79%

Does the media prefer LQDA or URGN?

In the previous week, Liquidia had 25 more articles in the media than Urogen Pharma. MarketBeat recorded 36 mentions for Liquidia and 11 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.40 beat Liquidia's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 16 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DFTX or URGN?

In the previous week, Urogen Pharma had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 11 mentions for Urogen Pharma and 7 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.66 beat Urogen Pharma's score of 0.40 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Urogen Pharma (URGN) Competitors

$38.26 -0.02 (-0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$38.54 +0.28 (+0.73%)

As of 07:39 PM Eastern

Compare

URGN vs. BLTE, LNTH, AMRX, LQDA, and DFTX

Should you buy Urogen Pharma stock or one of its competitors? Urogen Pharma's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Urogen Pharma compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Belite Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Urogen Pharma	-51.73%	N/A	-43.79%

In the previous week, Urogen Pharma had 9 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Urogen Pharma and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.22 beat Urogen Pharma's score of 0.40 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has higher earnings, but lower revenue than Urogen Pharma. Belite Bio is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Urogen Pharma	$109.79M	17.03	-$153.49M	-$1.98	N/A

Belite Bio presently has a consensus target price of $218.73, indicating a potential upside of 44.02%. Urogen Pharma has a consensus target price of $52.38, indicating a potential upside of 36.89%. Given Belite Bio's higher probable upside, equities analysts plainly believe Belite Bio is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Summary

Urogen Pharma beats Belite Bio on 7 of the 13 factors compared between the two stocks.

How does Urogen Pharma compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Lantheus presently has a consensus price target of $107.44, suggesting a potential upside of 7.42%. Urogen Pharma has a consensus price target of $52.38, suggesting a potential upside of 36.89%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Urogen Pharma is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

99.1% of Lantheus shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

In the previous week, Urogen Pharma had 5 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Urogen Pharma and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.63 beat Urogen Pharma's score of 0.40 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Urogen Pharma	-51.73%	N/A	-43.79%

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.16
Urogen Pharma	$109.79M	17.03	-$153.49M	-$1.98	N/A

Summary

Lantheus beats Urogen Pharma on 8 of the 15 factors compared between the two stocks.

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Urogen Pharma currently has a consensus price target of $52.38, suggesting a potential upside of 36.89%. Amneal Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 7.31%. Given Urogen Pharma's higher possible upside, research analysts plainly believe Urogen Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Urogen Pharma had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Urogen Pharma and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Urogen Pharma's score of 0.40 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	17.03	-$153.49M	-$1.98	N/A
Amneal Pharmaceuticals	$3.02B	2.07	$72.06M	$0.49	39.94

Amneal Pharmaceuticals has a net margin of 5.05% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Urogen Pharma compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Liquidia presently has a consensus price target of $83.69, suggesting a potential upside of 212.17%. Urogen Pharma has a consensus price target of $52.38, suggesting a potential upside of 36.89%. Given Liquidia's higher probable upside, equities research analysts clearly believe Liquidia is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Liquidia has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

In the previous week, Liquidia had 25 more articles in the media than Urogen Pharma. MarketBeat recorded 36 mentions for Liquidia and 11 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.40 beat Liquidia's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	16 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	15.16	-$68.92M	$1.37	19.57
Urogen Pharma	$109.79M	17.03	-$153.49M	-$1.98	N/A

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Urogen Pharma	-51.73%	N/A	-43.79%

Summary

Liquidia beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Definium Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Urogen Pharma	-51.73%	N/A	-43.79%

Definium Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 91.97%. Urogen Pharma has a consensus price target of $52.38, indicating a potential upside of 36.89%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Definium Therapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Urogen Pharma has higher revenue and earnings than Definium Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Urogen Pharma	$109.79M	17.03	-$153.49M	-$1.98	N/A

In the previous week, Urogen Pharma had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 11 mentions for Urogen Pharma and 7 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.66 beat Urogen Pharma's score of 0.40 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Urogen Pharma beats Definium Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.87B	$12.38B	$7.27B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	N/A	618.74	193.11	18.97
Price / Sales	17.03	744.73	561.77	81.05
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-17.00	9.20	10.71	6.03
Net Income	-$153.49M	$2.83B	$3.50B	$380.34M
7 Day Performance	-7.65%	-3.51%	-3.18%	-3.04%
1 Month Performance	-9.57%	-6.19%	-6.61%	-5.16%
1 Year Performance	128.28%	-5.64%	3.69%	-2.48%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	3.163 of 5 stars	$38.26 -0.1%	$52.38 +36.9%	+129.5%	$1.87B	$109.79M	N/A	291	News Coverage
BLTE Belite Bio	3.2686 of 5 stars	$169.82 +1.9%	$218.73 +28.8%	+100.0%	$6.71B	N/A	N/A	41	Positive News
LNTH Lantheus	3.487 of 5 stars	$99.53 +0.0%	$108.11 +8.6%	+87.0%	$6.50B	$1.54B	24.04	1,193	Analyst Forecast
AMRX Amneal Pharmaceuticals	3.948 of 5 stars	$20.14 -0.3%	$21.00 +4.3%	+100.9%	$6.45B	$3.02B	23.49	8,500
LQDA Liquidia	4.4152 of 5 stars	$30.26 -57.2%	$98.08 +224.1%	+19.2%	$6.33B	$158.32M	22.09	216	Trending News Insider Trade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Urogen Pharma compare to Belite Bio?

Summary

How does Urogen Pharma compare to Lantheus?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Summary

How does Urogen Pharma compare to Liquidia?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Urogen Pharma compare to Belite Bio?

Is BLTE or URGN more profitable?

Does the media favor BLTE or URGN?

Which has stronger valuation and earnings, BLTE or URGN?

Do analysts rate BLTE or URGN?

Do institutionals & insiders have more ownership in BLTE or URGN?

Which has more volatility & risk, BLTE or URGN?

Summary

How does Urogen Pharma compare to Lantheus?

Do analysts prefer LNTH or URGN?

Do insiders & institutionals believe in LNTH or URGN?

Which has more risk & volatility, LNTH or URGN?

Does the media favor LNTH or URGN?

Is LNTH or URGN more profitable?

Which has preferable valuation and earnings, LNTH or URGN?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Do analysts rate URGN or AMRX?

Does the media refer more to URGN or AMRX?

Which has better earnings & valuation, URGN or AMRX?

Is URGN or AMRX more profitable?

Do insiders & institutionals believe in URGN or AMRX?

Which has more volatility and risk, URGN or AMRX?

Summary

How does Urogen Pharma compare to Liquidia?

Do insiders & institutionals hold more shares of LQDA or URGN?

Do analysts prefer LQDA or URGN?

Which has more risk & volatility, LQDA or URGN?

Does the media prefer LQDA or URGN?

Which has stronger earnings & valuation, LQDA or URGN?

Is LQDA or URGN more profitable?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Is DFTX or URGN more profitable?

Do analysts rate DFTX or URGN?

Do institutionals and insiders believe in DFTX or URGN?

Which has more volatility & risk, DFTX or URGN?

Which has stronger earnings and valuation, DFTX or URGN?

Does the media favor DFTX or URGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools